

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Appropriations

Subcommittee: Labor, Health and Human Services, Education, and Related Agencies

Hearing Date: 04/09/2025

Hearing Title :

FY 2026 Public Witness

Witness Name: Colleen Kelley, MD, MPH, FIDSA

Position/Title: Chair, HIV Medicine Association (HIVMA)

Witness Type: ☐ Governmental ☒ Non-governmental

Are you representing yourself or an organization? ☐ Self ☒ Organization

If you are representing an organization, please list what entity or entities you are representing:

HIV Medicine Association (HIVMA)

FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.

HIV Medicine Association

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

See attached.

Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.

None

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

- ☒ I have attached a written statement of proposed testimony.
- ☒ I have attached my curriculum vitae or biography.

*Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B)(ii) shall include— (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.

Witne

4/1/25

Date

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

NIH, 1R01AI181732, 15498sc, \$977,801
NIH, UM1AI069418, \$15,492,022
NIH, 5T32AI157855, \$1,909,415
NIH, UM1 AI068619, PO24002514, \$1,383,793
CDC, 75D30123P17062, 00HCVJCG-2023-75890, \$249,288
NIH, HHSN2722013000121I/75N93019F00131, 000524040-T010-003 \$2,966,544
CDC, 75D30122P15647, 00HCVJCG-2022-70680, \$245,000
NIH, 5R01AI147839, \$3,454,262
CDC, 75D30122C14484, 00HCVJCG-2022-67978, \$450,000
NIH, UM1 AI068619, PO17001870, \$2,625,226
NIH, UM1 AI068619, PO19002009, \$56,647
NIH, 1R01AI174933, \$2,321,996
NIH, R01MH122341, \$3,746,448
NIH, 3UM1AI068614, 0001115111, \$649,671
NIH, 5R01HD092033-04, \$1,944,926
NIH, 3 UM1 AI068614, 0001041495, \$1,501,053
NIH, 3R01AI143875, \$6,662,234
NIH, R01GM141074, \$305,197
NIH, 5R01MH128130, \$3,105,053
NIH, P30AI050409, \$11,222,860
NIH, R01MH114892, \$5,782,425
NIH, R21AI57911, \$ 430,063
CDC, 75D30118C03204, 00HCVJCG-2020-54289, \$417,604

Infectious Diseases Society of America/ HIV Medicine Association

CDC BP2 2021-22, NU50CK000574-02-01, \$1,885,469
CDC BP3 2022-23, NU50CK000574-03-01, \$ 3,397,965
CDC BP4 2023-24, NU50CK000574-04-01, \$1,243,790
CDC BP5 2024-25, NU50CK000574-05-01, \$177,585
Fors Marsh, 75N98019D00007, \$200,000
Leidos, 75N91019D00024, \$186,123

Colleen Kelley, MD, MPH, FIDSA

Biography

Dr. Colleen Kelley is a faculty member in the Division of Infectious Diseases at Emory University School of Medicine with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health. She graduated from Emory University with her MD/MPH degree and completed her Internal Medicine residency at the University of California San Francisco and Infectious Diseases fellowship at Emory University. Dr. Kelley serves as the chair of the HIV Medicine Association (2024-2025).

Dr. Kelley has a multi-disciplinary background and previous clinical and research experience in HIV medicine, HIV epidemiology and clinical outcomes research, and laboratory-based HIV research. She cares for outpatients with HIV at the Grady Ponce de Leon Center and inpatients with HIV and other Infectious Diseases on the Infectious Diseases consult service and Special Immunology Service at Grady Memorial Hospital. The current focus of her research is on biomedical HIV prevention interventions including pre and post-exposure prophylaxis (PrEP and PEP) and HIV vaccines. She conducts translational immunology studies of HIV susceptibility in mucosal tissues to better HIV transmission. Dr Kelley is an investigator for the HIV Vaccine Trials Network and the HIV Prevention Trials Network. She is co-Director of the Emory Center for AIDS Research (CFAR) and serves as Associate Dean for Research at Emory.

Academic Appointment

Professor of Medicine, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine
Senior Physician, Emory University School of Medicine
Professor of Epidemiology, Department of Epidemiology, Rollins School of Public Health

Education

MD/MPH from Emory University School of Medicine
BA from University of Florida

Research

The broad focus of my research is on HIV and sexually transmitted infection (STI) prevention and spans mucosal immunology studies, clinical trials, and public health science. I conduct studies to better understand the immunology of human mucosal surfaces that influence HIV and sexually transmitted infection outcomes. I conduct and lead clinical trials for pre-exposure prophylaxis (PrEP), HIV vaccine candidates, and other interventions to improve sexual health. I collaborate on implementation science studies to better understand how PrEP and other sexual health interventions can improve health for all people.